Q1 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Lexicon Pharmaceuticals in a research report issued to clients and investors on Friday, March 7th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings of ($0.09) per share for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ Q2 2025 earnings at ($0.09) EPS and Q3 2025 earnings at ($0.10) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. The business had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%.

A number of other research firms also recently commented on LXRX. Leerink Partnrs downgraded Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners reaffirmed a “market perform” rating and set a $1.00 target price (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Finally, Piper Sandler decreased their target price on Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Price Performance

Shares of NASDAQ LXRX opened at $0.36 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The company has a market cap of $88.25 million, a PE ratio of -0.48 and a beta of 1.04. The business has a 50-day simple moving average of $0.71 and a two-hundred day simple moving average of $1.11. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets lifted its holdings in Lexicon Pharmaceuticals by 71.2% in the third quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 13,246 shares during the period. Bayesian Capital Management LP acquired a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $31,000. RPO LLC acquired a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Renaissance Technologies LLC acquired a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $38,000. Finally, Arizona State Retirement System lifted its holdings in Lexicon Pharmaceuticals by 34.4% in the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 16,136 shares during the period. 74.70% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.